相关实验视频
Updated: Jul 15, 2025

03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
479
宫癌:来自印度北部克什米尔的一个研究所经验
Shahida Nasreen1, Aabid R Lone1, Arshad Manzoor1
1Department of Radiation Oncology, Sheri Kashmir Institute of Medical Sciences SKIMS Soura UT, Srinagar, Jammu and Kashmir, India.
Journal of cancer research and therapeutics
|October 3, 2023
概括
宫癌在克什米尔很少见,但这项研究发现生存率与全球平均水平相似. 研究人员分析了138例病例,揭示了这一罕见恶性瘤的关键临床病理特征和治疗结果.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 流行病学 流行病学
背景情况:
- 宫癌是一个重要的全球健康问题,是全球第四常见的癌症.
- 相比之下,宫癌在克什米尔地区被认为是一种不常见的恶性瘤.
- 这项研究旨在阐明克什米尔宫癌患者的临床病理特征和生存率.
研究的目的:
- 在克什米尔的一家三级医院描述宫癌的临床病理特征.
- 确定该地区被诊断患有宫癌的患者的生存率.
- 将克什米尔的发现与全球宫癌数据进行比较.
主要方法:
- 从2015年1月到2019年1月,对138名宫癌患者的病历进行了回顾性分析.
- 数据收集包括患者人口统计,临床表现,治疗方式 (手术,放射治疗,化疗辐射) 和组织学.
- 使用Kaplan-Meier方法进行了生存分析,用于变量总结的描述统计数据.
主要成果:
- 呈现时的中位数年龄为56岁,大多数患者 (71.01%) 的表现状态为1.
- 大多数患者在20岁之前结婚 (79.71%) 和多夫妇 (61.59%).
- 状细胞癌是主要的组织学 (116例),大多数患者呈现II或III阶段的疾病. 三年无病生存率为54.34%,整体生存率为72.46%.
结论:
- 尽管在克什米尔是一个不常见的恶性瘤,可能是由于社会文化因素,宫癌表现出类似的治疗反应,毒性概况和全球观察到的生存结果.
- 这些发现强调了持续监测和管理子宫癌的重要性,即使在不太普遍的地区也是如此.
- 对克什米尔宫癌发生率和结果的特定社会文化影响的进一步研究可能是有必要的.
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K
Cancer
48.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.7K
Cancer Vaccines
396
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
396
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380

